


**ISSC 2023
Committee Report**

Committee Name : NSSP Evaluation Steering
Chairperson: Joel Hansel
Date of Meeting: 2020-2022
**Recorder: Kohl
Kanwit**

Approved
By: 
Printed Name: ~~Joel Hansel~~
Shannon Jenkins
(Substitute Chair)

Committee Members Present:

- | | | | |
|---|--|---|--|
| <input type="checkbox"/> Joel Hansel
(Chairperson) | <input checked="" type="checkbox"/> Kohl Kanwit | <input checked="" type="checkbox"/> Raymond Burditt
(FDA Delegate) | <input type="checkbox"/> John Jacobs
(NOAA) |
| <input checked="" type="checkbox"/> Shannon Jenkins | <input type="checkbox"/> Johnathan Gerhardt | <input checked="" type="checkbox"/> Bess Ormond
(FDA Advisor) | |
| <input checked="" type="checkbox"/> Kirk Wiles | <input type="checkbox"/> Bob Schuster | | |
| | <input checked="" type="checkbox"/> Kathy Browhawn | | |

Charges

Charge 1: Provide guidance to the following committees for development of evaluation criteria:

- 1. Growing Area Evaluation Criteria Committee**
- 2. In-Field Plant Evaluation Criteria Committee**
- 3. Control of Harvest Evaluation Criteria Committee**

This guidance should include:

- 1. A list of guiding principles that should be considered by committees charged to develop program evaluation criteria. The purpose of the development of these guiding principles is to ensure consistency in evaluation criteria across all program elements.**
- 2. Committee guidance may include development of a template which would include key components that should be included in all evaluation criteria.**

Findings/Conclusions:

Committee met in 2020 and worked on the in-field criteria that FDA uses. The Executive board gave interim approval for proposal 19-310 which will be voted on for full approval at this conference.

Bess Ormond provided that FDA has compared state performance from the past to see how they would fair with the new criteria. During 2020 and 2021 the in-field criteria could not be used because of the COVID pandemic, but it was used in 2022. FDA looked back from 2016 to 2021 and compared state performance and found that state compliance trended upward. Most states from 2021 were in conformance, some raised from provisional conformance. Comparison was not shared with individual states, but FDA is happy to do that on a state-by-state basis.

Charged with 19-305, 19-311 and 19-312

19-310 had an interim action and it is referred to General Assembly at this conference.

19-305 was originally referred to the Regulatory Relations, but that committee was dissolved and this proposal was transferred to PECC.

Recommendations:

Raymond Burditt made a motion to recommend no action be taken on this proposal (19-305) and Eric Hickey seconded. Rationale is that it is not appropriate MO language, and that FDA Specialists are already instructed to work with each state to figure out what works best for them. **MOTION WAS APPROVED**

Kirk Wiles made a motion that the committee recommend that FDA consult with states and seek permission for FDA specialist standardization at the same time. Seconded by Raymond Burditt. **MOTION WAS APPROVED**

19-311

Kirk Wiles made a motion to recommend no action on 19-311, seconded by David Wiggins. Rationale is that there has been progress made through proposal 19-310 so this is no longer necessary. **MOTION WAS APPROVED**

19-312

Raymond Burditt made a motion that PECC recommend that TF III refer proposal 19-312 to an appropriate committee. Eric Hickey seconded. **MOTION WAS APPROVED**

Kim motioned to adjourn, Raymond seconded. APPROVED